Your browser doesn't support javascript.
loading
FAM122A ensures cell cycle interphase progression and checkpoint control by inhibiting B55α/PP2A through helical motifs.
Wasserman, Jason S; Faezov, Bulat; Patel, Kishan R; Kurimchak, Alison M; Palacio, Seren M; Glass, David J; Fowle, Holly; McEwan, Brennan C; Xu, Qifang; Zhao, Ziran; Cressey, Lauren; Johnson, Neil; Duncan, James S; Kettenbach, Arminja N; Dunbrack, Roland L; Graña, Xavier.
Affiliation
  • Wasserman JS; Fels Cancer Institute for Personalized Medicine. Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
  • Faezov B; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
  • Patel KR; Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russian Federation.
  • Kurimchak AM; Fels Cancer Institute for Personalized Medicine. Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
  • Palacio SM; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
  • Glass DJ; Fels Cancer Institute for Personalized Medicine. Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
  • Fowle H; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
  • McEwan BC; Fels Cancer Institute for Personalized Medicine. Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
  • Xu Q; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Medical Center Drive, Lebanon, NH, USA.
  • Zhao Z; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
  • Cressey L; Fels Cancer Institute for Personalized Medicine. Temple University Lewis Katz School of Medicine, Philadelphia, PA, USA.
  • Johnson N; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Medical Center Drive, Lebanon, NH, USA.
  • Duncan JS; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
  • Kettenbach AN; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
  • Dunbrack RL; Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Medical Center Drive, Lebanon, NH, USA.
  • Graña X; Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
Nat Commun ; 15(1): 5776, 2024 Jul 10.
Article in En | MEDLINE | ID: mdl-38982062
ABSTRACT
The Ser/Thr protein phosphatase 2 A (PP2A) regulates the dephosphorylation of many phosphoproteins. Substrate recognition are mediated by B regulatory subunits. Here, we report the identification of a substrate conserved motif [RK]-V-x-x-[VI]-R in FAM122A, an inhibitor of B55α/PP2A. This motif is necessary for FAM122A binding to B55α, and computational structure prediction suggests the motif, which is helical, blocks substrate docking to the same site. In this model, FAM122A also spatially constrains substrate access by occluding the catalytic subunit. Consistently, FAM122A functions as a competitive inhibitor as it prevents substrate binding and dephosphorylation of CDK substrates by B55α/PP2A in cell lysates. FAM122A deficiency in human cell lines reduces the proliferation rate, cell cycle progression, and hinders G1/S and intra-S phase cell cycle checkpoints. FAM122A-KO in HEK293 cells attenuates CHK1 and CHK2 activation in response to replication stress. Overall, these data strongly suggest that FAM122A is a short helical motif (SHeM)-dependent, substrate-competitive inhibitor of B55α/PP2A that suppresses multiple functions of B55α in the DNA damage response and in timely progression through the cell cycle interphase.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Amino Acid Motifs / Protein Phosphatase 2 / Interphase Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Amino Acid Motifs / Protein Phosphatase 2 / Interphase Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2024 Document type: Article Affiliation country: Country of publication: